




Characteristics and treatment regimens across ERS SHARP severe asthma registries
van Bragt, Job J.M.H.; Adcock, Ian M.; Bel, Elisabeth H.D.; Braunstahl, Gert-Jan; ten Brinke,
Anneke; Busby, John; Canonica, Giorgio W.; Cao, Hui; Chung, Kian Fan; Csoma, Zsuzsanna;
Dahlen, Barbro; Davin, Elizabeth; Hansen, Susanne; Heffler, Enrico; Horvath, Ildiko; Korn,
Stephanie; Kots, Maxim; Kuna, Piotr; Kwon, Namhee; Louis, R.; Plaza, Vicente; Porsbjerg,
Celeste; Ramos-Barbon, David; Richards, Levi B.; Skrgat, Sabina; Sont, Jacob K.; Vijverberg,
Susanne J.H.; Weersink, Els J.M.; Yasinska, Valentyna; Wagers, Scott S.; Djukanovic, Ratko;
Maitland-van der Zee, A.H.; SHARP Clinical Research Collaboration; Assing, K.
Published in:
European Respiratory Journal





Accepted author manuscript, peer reviewed version
Link to publication from Aalborg University
Citation for published version (APA):
van Bragt, J. J. M. H., Adcock, I. M., Bel, E. H. D., Braunstahl, G-J., ten Brinke, A., Busby, J., Canonica, G. W.,
Cao, H., Chung, K. F., Csoma, Z., Dahlen, B., Davin, E., Hansen, S., Heffler, E., Horvath, I., Korn, S., Kots, M.,
Kuna, P., Kwon, N., ... Assing, K. (2020). Characteristics and treatment regimens across ERS SHARP severe
















Characteristics and treatment regimens across 
ERS SHARP severe asthma registries 
 
 
Job J.M.H. van Bragt, Ian M. Adcock, Elisabeth H.D. Bel, Gert-Jan Braunstahl, Anneke Ten Brinke, 
John Busby, Giorgio W. Canonica, Hui Cao, Kian Fan Chung, Zsuzsanna Csoma, Barbro Dahlen, 
Elizabeth Davin, Susanne Hansen, Enrico Heffler, Ildiko Horvath, Stephanie Korn, Maxim Kots, Piotr 
Kuna, Namhee Kwon, Renaud Louis, Vicente Plaza, Celeste Porsbjerg, David Ramos-Barbon, Levi B. 
Richards, Sabina Skrgat, Jacob K. Sont, Susanne J.H. Vijverberg, Els J. Weersink, Valentyna Yasinska, 




Please cite this article as: van Bragt JJMH, Adcock IM, Bel EHD, et al. Characteristics and 








This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 




Copyright ©ERS 2019 
 
Characteristics and treatment regimens across ERS 
SHARP severe asthma registries 
Job J.M.H. van Bragt1, Ian M. Adcock2, Elisabeth H.D. Bel1, Gert-Jan Braunstahl3, Anneke 
Ten Brinke4, John Busby5, Giorgio W. Canonica6, Hui Cao7, Kian Fan Chung8, Zsuzsanna 
Csoma9, Barbro Dahlen10, Elizabeth Davin11, Susanne Hansen12,  Enrico Heffler6, Ildiko 
Horvath9, Stephanie Korn13, Maxim Kots14, Piotr Kuna15, Namhee Kwon16, Renaud Louis17, 
Vicente Plaza18, Celeste Porsbjerg19, David Ramos-Barbon18, Levi B. Richards1, Sabina 
Skrgat20, Jacob K. Sont21, Susanne J.H. Vijverberg1, Els J. Weersink1, Valentyna Yasinska10, 
Scott S. Wagers22, Ratko Djukanovic23,  Anke H. Maitland-van der Zee1, on behalf of the 
SHARP CRC24. 
1Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, 
Amsterdam, The Netherlands  
2National Heart and Lung Institute, Imperial College London, London, United Kingdom  
3Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands  
4Medical Centre Leeuwarden, Leeuwarden, The Netherlands 
5Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's 
University Belfast, Belfast, United Kingdom 
6Personalized Medicine Clinic, Asthma and Allergy, Humanitas Clinical and Research 
Center, Humanitas University, Rozzano and SANI-Severe Asthma Network Italy, Milan, Italy  
7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  
8Airway Disease, National Heart and Lung Institute, Imperial College London, London, 
United Kingdom  
9National Koranyi Institute of Pulmonology, Budapest, Hungary 
10Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska 
University Hospital, Huddinge, Sweden  
 
11European Lung Foundation, Sheffield, United Kingdom 
12Center for Clinical Research and Disease Prevention, Bispebjerg and Frederiksberg 
Hospital, The Capital Region, Copenhagen, Denmark  
13Universitätsmedizin Mainz, Mainz, Germany  
14Chiesi Farmaceutici, Global Clinical Development, Parma, Italy  
15Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, 
Poland  
16Respiratory Medical Franchise, GSK, Brentford, United Kingdom  
17Department of Pulmonary Medicine, Centre Hospitalier Universitaire (CHU), GIGAI3 
Research Group, Liege University, Liege, Belgium  
18Respiratory Medicine Department & Biomedical Research Institute, Hospital de la Santa 
Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain  
19Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University 
Hospital, Copenhagen, Denmark 
20University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia 
21Department of Biomedical Data Sciences, section Medical Decision Making, Leiden 
University Medical Center, Leiden, The Netherlands 
22BioSciConsulting, Maasmechelen, Belgium 
23NIHR Southampton Respiratory Biomedical Research Unit, Faculty of Medicine, University 
of Southampton, Southampton, United Kingdom 








Corresponding author: Job J.M.H. van Bragt 
Amsterdam UMC, location AMC 
Department of Respiratory Medicine, room F5-260 
Meibergdreef 9 
1105 AZ, Amsterdam 
The Netherlands 
T: +31-(0)20-5661660 |  E: j.j.vanbragt@amsterdamumc.nl 
 
Take home message 
The severe asthma population in Europe is heterogeneous and differs in clinical 
characteristics and treatment. Harmonisation across registries and guidelines is needed and 
requires collection of same data across cohorts to enable future research in SHARP. 
 
Plain Language Summary 
What is it about? 
Severe asthma is a very serious condition with a large impact on the life of patients. 
Researchers from different countries in Europe have systematically collected data from 
severe asthma patients in registries. This study was set up to provide an overview of what 
data is currently collected in those registries and to show what differences exist between 
patients with severe asthma in different countries in Europe. We found that many differences 
exist between the characteristics of patients in different European countries. We also found 
that treatment of patients with severe asthma is different across European countries.  
 
Why is it important? 
Much is still  unknown about severe asthma and it seems to be a very complex disease. The 
current study can help to provide a view on what is considered severe asthma in different 
countries in Europe. This is important to provide new insights in what is necessary for doing 
research in a large scale registry across European countries and, in addition, to make sure 
that registries across Europe use the same standards and definitions.   
 
Abstract 
Little is known about the characteristics and treatments of patients with severe asthma 
across Europe but both are likely to vary. This is the first study in the ERS Severe 
Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) and it is designed 
to explore these variations. Therefore, we aimed to compare characteristics of patients in 
European severe asthma registries and treatments before starting biologicals. This was a 
cross-sectional retrospective analysis of aggregated data from 11 national severe asthma 
registries that joined SHARP with established patient databases. Analysis of data from 3,233 
patients showed many differences in characteristics and life style factors. Current smokers 
ranged from 0% (Poland, PL, Sweden, SE) to 9.5% (Belgium, BE), mean BMI ranged from 
26.2 (Italy) to 30.6 kg/m2 (UK) and the largest difference in mean pre-bronchodilator FEV1% 
pred. was 20.9% (Netherlands vs Hungary). Before starting biologicals patients were treated 
differently between countries: mean ICS dose ranged from 700-1335 µg/day between those 
from Slovenia (SL) vs PL when starting anti-IL-5 antibody and from 772-1344 µg/day in 
those starting anti-IgE (SL vs Spain). Maintenance OCS use ranged from 21.0% (BE) – 
63.0% (SE) and from 9.1% (Denmark) to 56.1% (UK) in patients starting anti-IL-5 and anti-
IgE, respectively. The severe asthmatic population in Europe is heterogeneous and differs in 
both clinical characteristics and treatment, often appearing not to comply with the current 
ERS/ATS guidelines definition of severe asthma. Treatment regimens before starting 









The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP)  was 
set up in 2018 to harmonise severe asthma management across Europe and unravel 
underlying heterogeneity in a patient-centred way [1]. The current project involves the first 
structured assessment and comparison of national severe asthma registries that are part of 
SHARP to discover strengths/weaknesses in those registries and to evaluate severe asthma 
and its treatment across Europe.  
 
Significant progress has been made in the field of severe asthma since the turn of the 
millennium [2]. Especially, the introduction of novel biologicals for patients with severe 
asthma, has provided new effective options for medical treatment, beginning with the anti-
IgE monoclonal antibody, omalizumab, and more recently anti-IL-5 antibodies, mepolizumab, 
reslizumab and benralizumab. The use of these biologicals is often restricted to patients who 
fulfil the definition of severe asthma according to ERS/ATS guidelines in whom all potential 
aggravating factors have been eliminated and pre-specified criteria fulfilled, such as high 
dose ICS/LABA treatment, multiple exacerbations in the previous year and/or chronic use of 
oral glucocorticoids [3].  
 
The most recent GINA difficult-to-treat and severe asthma guide introduces a new approach 
to the management of asthma [4], better reflecting the recommendations of the Lancet 
commission on asthma [5, 6] that highlighted the need for a multidimensional assessment 
and the introduction of treatable mechanisms in asthma management. However, the 
definition of severe asthma is still not unambiguous and it has been suggested that an 
improved definition, including risk assessment and a better reflection of clinical reality, 
should be established. Asthma death is arguably the most severe outcome, but most deaths 
occur in patients with non-severe asthma with low levels of treatment [7]. Many disease 
aggravating factors, both patient related (e.g. psychological factors, co-morbidities) and 
environmental, (airborne allergens, air pollution), socio-economic (housing, health insurance) 
 
and health care accessibility factors, are difficult or impossible to eliminate. Furthermore, the 
expertise of the treating physician and the facilities of the treatment centre are likely to 
influence levels of asthma control. Finally, the choices of treatment (including starting 
biologicals) are effected by differences in health care systems, reimbursement policies and 
accessibility to medication.  
 
In the present study, we explored the prevalence as well as the characteristics of patients 
with “severe asthma” reported by physicians, which are likely to differ depending on the 
region, climate, health care system and expertise of the treatment team. Furthermore, we 
explored the severity of disease (using the treatment of the patient and biomarkers as a 
proxy) of severe asthma patients before starting biologicals, also expecting differences 
between European countries. We compared the characteristics of those patients who started 
with high-cost therapies (biologicals, bronchial thermoplasty, high altitude revalidation) within 
these registries, and stratified the patient cohort for the two most commonly used groups of 
biologicals (anti-IL5 and anti-IgE). This study showed the need for harmonisation across 
registries and guidelines and the requirement to collect a same set of minimal clinical data 
across cohorts which will enable better co-ordination of treatment efforts using biologicals 
across Europe. 
 
Materials and methods 
Study subjects 
Data from 11 different European national registries for severe asthma (figure 1) were eligible 
for inclusion in the analysis. There were no general inclusion criteria provided for the patients 
in these registries, so these differed between registries (figure 2). Most European registries 
included patients who fulfilled the severe asthma criteria according to the joint ERS/ATS 
guidelines [3], but in some cases national asthma guidelines were used or all patients who 
attended specialist asthma centres were qualified for inclusion. Four registries focused 
enrolment into registries of patients that were either in the process of being considered for or 
 
were starting treatment with biologicals. One registry selected only patients with a smoking 
history <5 pack-years and one registry included all patients who attended specialist referral 
centres for severe asthma. 
 
Study design 
This study was a cross-sectional, retrospective analysis of aggregated registry data. In view 
of the restrictions imposed on data confidentiality before and, in some cases, after imposition 
in the European Union of the General Data Protection Regulation (GDPR), data were 
received from individual national registries in aggregate form composed of counts (with 




A descriptive comparison was performed for the clinical characteristics in the different 
registries. To describe differences in treatment regimens and biomarkers, comparisons were 
made prior to starting high-cost therapies. For those patients who had already discontinued 
these therapies, and where information before start was not available, data from more than 6 
months after stopping of high-cost therapies was used. High-cost therapies were defined as 
treatments with biologicals, bronchial thermoplasty or high-altitude treatment.  
 
Results 
Data from a total of 3,233 patients classified as having severe asthma by the 11 different 
European registries were used for the analysis. Table 1 indicates the abbreviations that are 
used to identify the different countries. The registries varied in size (Sweden, SE; n= 27 – 
UK; n=765). The characteristics of the different populations are shown in table 2. None of 
the participating registries collected the full set of variables requested. Data that were not 
collected or not available in a registry are shown in the different tables.  
 
 
Differences in baseline clinical characteristics. 
The mean age of patients ranged from 44.4 (Germany, DE) to 58.3 years (Hungary, HU). 
The percentage of males ranged from 30% (Slovenia, SL) to 51.9% (SE). Current smokers 
ranged from 0% (Poland, PL and SE) - 9.5% (Belgium, BE). The percentage of ex-smokers 
varied from 10.8% (HU) to 41.3% (The Netherlands, NL); in Hungary, only patients with a 
smoking history of <5 pack-years were enrolled into the registry. Half of the registries 
predominantly included patients with adult-onset severe asthma (NL, UK, HU, SE, Denmark, 
DM, and SL), while four registries consisted mainly of patients with childhood-onset asthma 
(BE, Italy, IT, PL and DE). Based on mean FEV1 and FVC (% of predicted), patients in the 
Dutch registry had the best lung function, while those in the Hungarian had the worst lung 
functions (FEV1: 76.9% vs. 56.0%  and FVC: 98.3% vs. 76.6%). Median blood eosinophil 
levels varied from 0.230 x 109 cells/ml (NL) to 0.800 x 109 cells/ml (SE), median serum total 
IgE varied from 144 IU/ml (NL) to 275 IU/ml (SE) and median FeNO varied from 25 ppb (BE) 
to 66 ppb (SL). Between 54.6% (IT) and 100% (HU, SE) of the patients were uncontrolled as 
judged from patient-reported questionnaire scores (ACQ or ACT). 
 
Most registries enrolled patients being treated in a tertiary care centre; however, a small 
group of patients was included in primary care (ES) and four registries (ES, NL, BE and HU) 
included up to 33.8% in secondary care hospitals. In most registries >90% of the patients 
were treated according to GINA step 4 or 5 guidelines [7]; in DM this was 77.6% (evaluated 
before patients started biologicals) and in 6 registries (HU, PL, SE, DE, IT, SL) 100% of 
patients were at step 4 or 5. The percentage of patients on biologicals ranged from 0% (SE) 
to 71.0% (PL). The most frequently given biological in 7 registries was anti-IgE (BE, ES, HU, 
PL, SE, DE, IT, SL), and in 3 registries it was anti-IL5 (NL, UK, DM). The registries in NL, BE 
and SL enrolled patients who had undergone bronchial thermoplasty and the registry in NL 
also included patients who had received high-altitude treatment (14%). The mean ICS dose 
(fluticasone equivalent dose) ranged from 491±163 µg/day (SL) to 1225±445 µg/day (ES). 
The maintenance OCS median dose ranged from 7.5 mg/day (HU) to 10.7 mg/day (IT). 
 
 
Treatment regimens of patients starting high cost therapies 
Table 3 shows medication data of 1,962 patients included in the registries prior to starting or 
>6 months after stopping high cost therapies. In 6 registries (BE, ES, HU, SE, SL, DM), most 
patients were not treated according to GINA treatment step 5. Short-acting β-agonists were 
the most used reliever medications in all but one registry (ES) where the most frequent 
relievers were short-acting muscarinic antagonist (SAMA). SABA and/or SAMA use varied 
between 4.0% (IT) to 100% (HU, PL, SE). Long-acting beta-agonist (LABA) use varied from 
80.3% (PL) to 100% (IT, HU and SE). Long-acting muscarinic antagonists (LAMA) were 
used in all countries and varied from 14.0% (HU) to 56.8% (UK). In 7 registries (ES, HU, PL, 
SE, IT, SL, UK) all patients were on ICS, while in NL,  BE and DM this was 99.3%, 97.0% 
and 93.9% respectively. Mean fluticasone equivalent doses ranged from 1320±465 µg/day 
(ES) to 570±497 µg/day (IT).  
 
Figures 3 and 4 provide an overview of maintenance therapy for severe asthma patients 
before starting with anti-IL5 biologicals (mepolizumab, reslizumab or benralizumab; n=577) 
and anti-IgE biologicals (omalizumab; n=553). In most of the registries, all patients were on 
ICS before starting anti-IL5 (in DM this was only 94.7%), although there were differences in 
ICS-dose, ranging from 1335±529 (PL) to 700±118 µg/day (SL). Information on treatment 
before starting omalizumab was available in 6 registries. ICS use was less than 100% in BE 
(96.6%) and DM (90.9%) and the mean dose ranged from 1344±540 (ES) to 772±191 
µg/day (SL). In four registries, all patients were using LABA before starting anti-IL5 (ES, HU, 
SE, SL), while in other countries this ranged from 25.0% (PL) to 94.4% (NL). LAMA use in 
anti-IL5 starting patients varied between 0% (HU) and 79.1% (SL). LAMA use in anti-IgE 
starting ranged from 12.5% (HU) – 100% (SL). OCS was used as a maintenance therapy 
before starting with anti-IL5 in all registries and ranged from 21.0% (BE) – 63.0% (SE) of the 
population. Before starting anti-IgE, OCS was also used in all registries, varying between 
9.1% (DM) and 56.1% (UK) of the population. 
 
 
Table 4 shows differences between registries in biomarkers before starting treatment with 
biologicals. Median blood eosinophil levels before starting anti-IL5 therapy were higher than 
levels seen before starting anti-IgE treatment in all registries. The levels of median blood 
eosinophils before starting anti-IL5 treatment ranged from 0.270 x109 cells/L (DM) to 0.800 
x109 cells/L (SE). The median concentrations of serum total IgE  before start with anti-IgE 
treatment ranged between 118 IU/ml (SL) to 324 IU/ml (UK). 
 
Discussion 
This first collaborative study in the SHARP consortium has made several important 
observations. Across Europe there are large differences in characteristics and life style 
factors of patients with severe asthma. Treatment regimens and biomarkers in patients 
starting biologicals and criteria for their prescription also seem to differ between countries. 
The patients included in the various countries of Europe for treatment with biologic therapies, 
who we would consider to suffer from severe asthma, did not fit the criteria of the definition 
of severe asthma as defined by ERS/ATS and GINA, and they also did not meet the criteria 
used to recruit patients in the Phase 3 trials of these biologic therapies.  The reasons for 
these differences are as yet unclear and will need to be addressed as the SHARP CRC 
moves to harmonize the data that are collected in the different national registries.  
 
Differences between registries 
The data in this study clearly shows large variation in the baseline characteristics of 
asthmatics enrolled in the 11 European registries. This could be due to differences in the 
definition of severe asthma across the different registries. The disparities could, in principle, 
also reflect differences in overall severity of the broader asthma population in each country, 
however our data do not allow us to explore to what extent the enrolled patients reflect the 
general asthma population. Lung function results, expressed as pre-BD FEV1 and FVC (% of 
predicted), were in both cases highest in NL and lowest in HU, with differences as high as 
 
20.9% and 21.7%, respectively. We do not presently know what causes these differences; 
patients in the two registries were on similar treatment, and FENO levels and blood 
eosinophil counts were not different. However, possible explanations may be in differences 
in life-time dose or onset of therapy with ICS, which would result in progressive loss of lung 
function, or in the difference in OCS use between HU and NL (60% vs. 26% before high-cost 
therapies) and the resulting effects on blood eosinophils and FeNO. Important differences 
were also found in the percentage of adult onset asthma patients (64.9%), a clinical 
phenotype of asthma that is known to be more severe than early-onset asthma [8]. 
Furthermore, the percentages of patients with uncontrolled asthma based on questionnaire 
scores (45.4 % difference) and asthma-related hospitalization during the past 12 months 
(43.5% difference) point to possible differences in the quality of care (e.g. access to 
specialist care). Other potential explanations might be exposure to asthma triggers like 
outdoor and/or indoor pollution (including cigarette smoke) that may have resulted in 
worsening lung function. Whilst these factors could not be assessed in the current analysis 
because relevant data were not collected, they could be the subject of future studies by the 
SHARP CRC. 
 
Smoking patients, or smokers with a history ≥10 pack-years are almost never included in 
asthma trials due to the risk of confounding effects of smoking and the undesired inclusion of 
COPD patients. In real life, however, significant proportions of severe asthma patients also 
smoke, with rates in excess of 4% found in BE, UK, ES and HU. Again, differences between 
registries from different countries were large, up to 30.7 %-points for the percentage of 
never-smokers, with differences in median pack-years of >14 years. Interestingly, 
differences in smoking do not necessarily reflect the differences in lung function; the 
Netherlands included more ex-smokers and median pack-years is higher than in Hungary 
despite patients in Hungary having worse lung functions. In general, BMI appeared to be 
less variable. Nevertheless, the largest difference here was 4.4 kg/m2 and the difference in 
 
average BMI between the UK (30.6 kg/m2) and Italy (26.2 kg/m2) suggests that obesity in 
severe asthma patients may be a significant problem in the UK, but not in Italy.  
 
Treatment of patients starting on high-cost therapies 
The differences in OCS use before starting high-cost therapies between registries from 
different countries was striking. The percentage of patients on maintenance OCS varied 
greatly (largest difference: 61.6 %-point between IT and ES), suggesting very different 
prescribing regimens across Europe. When specifically studying patients starting anti-IL5 
and omalizumab, large differences in treatment regimens were also found. OCS use in those 
starting anti-IL5 treatment were highest in the UK and differed most from the clinical practice 
in Belgium (52.2% difference). As expected, all patients starting anti-IL5 biologicals were 
using regular ICS, although there was marked variation in the daily dose, with fluticasone 
equivalent differences of up to 635 µg/day (PL vs SL). Why this is the case is unclear. 
Potential explanations, which will require focused study by the SHARP CRC, include cost of 
treatment and fear of high-dose treatment related side-effects. 
 
Patients starting omalizumab showed similar differences between registries, with largest 
differences in OCS use and mean dose between the UK and Belgium (45.1 %-points and 
10.0 mg/day respectively). All patients starting omalizumab were on ICS except for Belgium, 
and the largest fluticasone equivalent difference was 571 µg/day (ES vs SL). LAMA can be 
used as step-up treatment after GINA step 4 [9] and the results show that the percentage of 
patients on LAMA in both anti-IL5 and anti-IgE varied significantly. LAMA use was common 
in Slovenia, although this observation was based on a small sample size (24 starting ant-IL5 
antibody and 9 starting Omalizumab). Of note, LAMA were hardly used in Hungary, Poland 
and Spain. Taken together, these differences in treatment suggest a difference in criteria 




Deviations from guidelines and trial criteria 
An important issue that this study highlights is that criteria on which severe asthma is 
defined currently by international guidelines and those used in clinical trials with biologicals 
do not match clinical reality. For example, not all patients enrolled in the registries are on 
GINA step 4/5 treatment and ICS doses in patients starting with biologicals do not always 
correspond to those applied as inclusion criteria in trials and in the joint ERS/ATS criteria. 
Fluticasone equivalence of >1000μg/day (ex-actuator; 880μg/day) was an inclusion criterion 
for mepolizumab trials [10, 11] and doses >1000μg/day are considered high-dose according 
to the ERS/ATS guidelines [3]. In this study, patients in several registries (BE, UK, ES, HU, 
SL) were on mean doses <1000μg/day, suggesting that a significant proportion of patients in 
the registries would not meet the mepolizumab trial inclusion criteria or do not meet the 
international ERS/ATS criteria for severe asthma. This deviation in ICS dose can be 
potentially explained by different interpretations between what is considered high dose ICS 
by the ERS/ATS and GINA (>500µg/day fluticasone equivalents). Additionally, for the BE 
registry, these data can be partially explained by to the inclusion of a large number (roughly 
25-30%) of non-T2 asthma patients, who may be less responsive to ICS. A similar picture 
arises with anti-IgE treatment. Mean fluticasone equivalent ICS doses before starting 
omalizumab were <1000μg per day in Belgium, the UK and Slovenia; thus, at least part of 
the population does not have severe asthma according to international ERS/ATS guidelines.  
 
The first clear message that arises is the need for agreement between ERS/ATS guidelines 
and GINA, as the current differences in definitions are a cause for confusion among 
pulmonary physicians. One of the possible explanations of the differences between the 
characteristics of patients included in the severe asthma registries and the characteristics 
that were expected according to ERS/ATS guideline definition of severe asthma might 
suggest that some patients do not fulfil guideline criteria but are being considered as having 
severe asthma by clinical severe asthma experts. These differences will require more 
analysis, including the processes whereby biologics are offered to patients. In the UK, the 
 
main criteria required by the National Institute of Clinical Excellence for both omalizumab 
and anti-IL5 biologicals is the frequency of exacerbations (three – four) in the previous 12 
months or maintenance OCS [12–14], and these are implemented rigorously by the 
commissioning groups that regulate the use of biologicals. One plausible explanation for the 
observation in the UK is that the frequency of exacerbations is not used to define asthma 
severity. Furthermore, patients treated with biologicals in clinical practice do not always fulfil 
the criteria that were used for inclusion in the biological trials. Although this study was not 
designed to evaluate the efficacy of biological therapies, this suggests a need for 
observational studies targeting the efficacy of biologicals in patients who were not enrolled in 
trials that resulted in their approval. Such observational studies would provide more insight in 
the efficacy of biologicals in daily practice; however, the differences in countries as 
described here should be considered.   
 
European harmonisation 
The previous issues raise awareness that severe asthma research needs to consider more 
the complexity and heterogeneity between different populations of chronic respiratory 
diseases. New discoveries will need large amounts of data that can only be collected in 
international consortia, therefore there is an urgent need to harmonize datasets on severe 
asthma across Europe. An international consensus needs to be reached on a minimal set of 
variables that should be collected in the national registries that take part in SHARP. When 
studying lung function, for example, all registries currently include information on pre-
bronchodilator (BD) FEV1, but only 9 out of 11 registries also record pre-BD FVC. 
Information on lung function reversibility is even less common, with post-BD FEV-1 currently 
recorded in only 7 registries. The bigger challenge, however, lies in the harmonization of 
definitions of variables. The definition for FEV1 and FVC is rather simple, whilst it is not 
straightforward for adherence to therapy. Countries retrieved these data in different ways; by 
checking prescription records, check-up by a dedicated asthma nurse, by doctor‟s 
assessment or checking a database whether a patient was registered as showing „good 
 
compliance‟. Accordance on a minimal set of well-defined key variables is needed to 
increase the usability of the SHARP platform and should be subject of future studies. The 
data collected in this study should be a stepping-stone to start the discussion about more 
standardized practice for severe asthma care in Europe.  
 
Earlier research 
Several of the participating registries have already published analyses of their data [15–17]. 
The heterogeneity found in this study is in line with the analyses of registries in Belgium, Italy 
and the UK, where differences in inflammatory characteristics [15] amongst patient 
populations were found even between centres in the same country [16] and differences in 
phenotype were identified [17]. Analyses of other international cohorts also show a marked 
heterogeneity across severe asthma patients. The pan-European U-BIOPRED cohort has 
provided evidence for the existence of different phenotypes and endotypes of severe asthma 
as well as evidence for „cluster-migrating‟ patients [18]. The American Severe Asthma 
Research Program (SARP) cohort has also shown that heterogeneity exists even within 
clinical clusters [19]. Our present study further confirms that the severe asthma phenotype 
may be an oversimplification of the clinical reality and that different phenotypes with different 
therapeutic needs exist within the population of severe asthma patients currently viewed as 
a single group. Large differences in prevalence of severe asthma that have been described 
[20] support the idea that current guidelines may be ambiguous.  
 
Strengths/limitations 
This first ever attempt to integrate registry data across Europe has limitations. With over 
3,000 patients included in the analysis, this is one of the largest comparisons of this 
population to date, providing insight into the characteristics and treatments of this 
heterogeneous group across Europe. With representation from South-, West-, Eastern- and 
Northern Europe there is a good geographical distribution and thus, the influence of 
differences in environmental and genetic factors and in healthcare systems have been 
 
incorporated but to what extent these influence the observed heterogeneity is unclear. 
Perhaps the biggest, but inevitable, weakness is the retrospective nature of the study. 
Indeed, there was significant variation in inclusion criteria and only half the registries used 
the joint ERS/ATS definition of severe asthma. Furthermore, not all patients were treated in 
a specialized asthma centre while half the registries solely included patients in tertiary care, 
reflecting diversity in what clinicians in different European countries consider to be severe 
asthma. A further important limitation of the current data is preselection of specific patient 
subgroups; particularly the registries in Netherlands, Sweden and Slovenia focused on 
including patients that were starting biological therapies which is expected to result in 
cohorts composed of the most severe patients. However, we expected this preselection of 
more severe patients to be reflected in a selection of patients who met the current 
international guidelines but that was not the case. Some registries, i.e. Sweden and Belgium, 
are currently run in only one city or even one hospital, which implies that data not 
necessarily reflects a country but sometimes a specific situation in a country.  
 
Conclusion 
In summary, this study shows that the population of severe asthma patients in Europe is 
heterogeneous and differs in both clinical characteristics and treatment. These results lead 
to several key implications. First, severe asthma populations and treatment, even when 
biological users are excluded, greatly differ between countries. Thus, results from single 
centre trials, or even multicentre trials in the same country, cannot necessarily be 
extrapolated to other countries. Second, the definition of severe asthma in current guidelines 
does not comply with characteristics of real-world severe asthma patients; therefore, there 
might be differences in the application of these guidelines in the different countries. Third, 
the first key messages underline the importance of harmonization of severe asthma 
databases across Europe and the need for long-term follow-up of the patient. A consensus 
on the data that must be collected to provide solutions to these challenges should be agreed 
and this will provide a logical next step for the SHARP consortium. Of importance to future 
 
research in the SHARP CRC, the use of aggregated data proved to be a relatively easy way 
to obtain data that can be used for international collaboration.  
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Belgium Italy Spain 
The 
Netherlands 
Germany Poland Slovenia Hungary Denmark Sweden 
Number of patients, n 765 629 434 410 237 209 193 140 130 59 27 
Age, years (SD) 47.6 (14.5) 56.9 (14.7) 54.1 (13.7) 56.4 (14.8) 52.8 (14.2) 44.4 (20.4) 48.4 (14.6) 53.5 (12.8) 58.3 (12.9) 51.9 (16.1) 50 (8.6) 




Current  30 (4.1) 60 (9.5) 12 (2.7) 29 (7.1) 2 (0.9) 5 (2.4) 0 (0) 1 (0.7) 8 (6.2) 2 (4.0) 0 (0) 
Never 
smoker 
526 (71.7) 368 (58.5) 352 (80.5) 281 (68.5) 136 (57.9) 125 (59.8) 171 (88.6) 92 (65.7) 108 (83.1) 24 (48.0) 16 (59.3) 
Ex-
smoker 
178 (24.3) 201(32.0) 73 (16.7) 100 (24.4) 97 (41.3) 79 (37.8) 22 (11.4) 47 (33.5) 14 (10.8) 19 (38.0) 11 (40.7) 
Pack-years, median (IQR) 15 (5-20) 15 (6-27) 9 (4-15) 19 (10-23) 10 (4-19) 8 (2-15) 12.5 (15) 10 (3-20) <5 PY  8.5 (2.2-15) 5 (4-9) 
BMI, kg/m
2
 (SD) 30.6 (7.4) 27.7 (12.6) 26.2 (5.0) 28.2 (6.0) 28.3 (5.4) 27.4 (10.8) 28.1 27.1 (5.8) 26.9 (5.4) 27.1 (5.4) 27.7 (5.3) 
FEV1, %pred (SD) 67.8 (22.8) 67.9 (21.6) 71.4 (20.2) 68.1 (36.1) 76.9 (22.2) 70.3 (23.0) 63.2 (23.5) 69.6 (19.8) 56.0 (16.8) 72.0 (19.1) 66.0 (19.9) 
FVC, %pred (SD) 85.3 (19.8) 88.2 (20.2) 88.2 (21.1) NA 98.3 (20.5) 84.9 (19.7) NA 95.0 (15.6) 76.6 (18.5) 78.2 (18.3) 86.8 (19.6) 
Eosinophils x10
9

































































FeNO ppb, median (IQR) 41 (23-77) 25 (14-42) 32 (17-64) 33 (19-52) 33 (20-60) 33 (19-79) 27 (27) 66 (27-101) 32 (18-56) 26 (13-49) 57 (29-80) 
Adult-onset asthma, n (%) 385 (59.8) 200 (31.8) 105 (24.0)  NA 129 (63.2) 61 (39.4) 68 (35.2) 110 (78) 89 (68.5) 26 (76) 24 (88.9) 
ACQ, mean (SD) 3.0 (1.3) 2.5 (1.3) 2.9 (1.5) NA 2.1 (1.2) 2.6 (1.5) 3.3 (0.9) NA NA 2.4 (1.4) 1.8 (1) 
ACT, mean (SD) NA 13.2 (5.4) 17.2 (5 .4) 15.9 (5.8) NA 15 (6.0) 12.3 16.7 (5.5) 16.6 (1.2) NA 12 (3.8) 
Uncontrolled  based on 
ACQ/ACT, n (%)  
581 (84.6) 331 (76.1) 250 (54.6) 221 (68.8) 88 (61.5) 135 (71.1) 191 (99) 87 (64.0) 130 (100) 21 (70) 27 (100) 







0 (0) 0 (0) 0 (0) 16 (3.9) 0 (0) NA 0 (0) 0 (0)  0 (0) 0 (0) 0 (0) 
Secondar
y care 
0 (0) 52 (8.3) 0 (0) 125 (30.5) 76 (32.1) NA 0 (0)  0 (0)  44 (33.8) 0 (0) 0 (0) 
Tertiary 
care 
765 (100.0) 577 (91.7) 437 (100) 269 (65.6) 161 (67.9) NA 193 (100) 139 (100) 86 (66.2) 59 (100) 27 (100) 
GINA 4 treatment, n (%) 162 (21.2) 309 (49.0) 18 (5.7) 197 (48.1) 113 (47.7) 130 (62.2) 53 (27.5) 87 (62.6) 93 (71.5) 24 (49.0) 15 (55.6) 
GINA 5 treatment, n (%)  569 (74.4) 320 (51.0) 297 (94.3) 210 (51.2) 118 (49.8) 79 (37.8) 140 (72.5) 52 (37.4) 37 (28.5) 14 (28.6) 12 (44.4) 
Biological use,  
n (%) 
total 479 (64.5) 160 (25.0) 215 (49.5) 210 (51.2) 82 (34.6) 80 (38.3) 137 (71.0) 66 (47.4) 30 (23.1) 59 0 (0) 
Anti-IgE 115 (25.4) 130 (21.0) 180 (41.2) 197 (48.1) 29 (12.2) 41 (19.6) 129 (66.8)  59 (42.4) 16 (12.3) 18 (30.5) 0 (0) 
Anti-IL5 337 (74.4) 30 (5.0) 35 (8.1) 13 (3.2) 53 (22.4) 39 (18.7) 8 (4.1) 7 (5.0) 14 (10.8) 41 (69.5) 0 (0) 
Anti-
IL4/IL13 
1 (0.2) 0 (0) NA 0 (0) 0 (0) NA 0 (0) 0 (0) 0 (0) 0 0 (0) 
Thermoplasty, n (%) 0 (0.0) 9 (1.4) NA 0 (0) 3 (1.3) NA 0 (0) 2 (1.4 ) 0 (0) 0 0 (0) 
High altitude treatment, n (%) NA 0 (0) NA 0 (0) 33 (14) NA 0 (0) 0 (0) 0 (0) NA 0 (0) 
ICS* mean dose (SD) 934 (449) 954 (501) 542 (489) 1225 (445) 1027 (737) 676 (398) 1220 (668) 491 (163) 920 (370) 1073 (372) 1196 (641) 
OCS
†
















7.5 (5.0-10.0) NA 
10.0 (7.5-
10.0) 
Data are represented as mean with standard deviation (SD) unless otherwise specified. IQR: Interquartile range from quartile 1 – quartile 3, BMI: body mass 
index, FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, FeNO: fraction of exhaled Nitric Oxide, ACQ: asthma control questionnaire, 
ACT: asthma control test, GINA: Global Initiative for asthma, ICS: inhalation corticosteroids, OCS: oral corticosteroids. *: dose expressed as fluticasone 
equivalents, †: dose expressed as prednisone equivalents. 
  
 





Belgium Italy Spain Poland 
The 
Netherlands 
Hungary Slovenia Denmark Sweden Germany 
  n 477 469 219 210 193 143 100 73 49 27 NA 
GINA step 4, n (%) 152 (31.9) 347 (74) 2 (2.0)  166 (79.0) 53 (27.5) 54 (37.8) 74 (74.0) 42 (57.5)) 24 (49) 15 (55.6) NA 
GINA step 5, n (%) 325 (68.1) 109 (23) 98 (98.0)  44 (20.9) 140 (72.5) 87 (60.8) 26 (26.0) 31 (42.4) 14 (29) 12 (44.4) NA 
SABA, n (%) 444 (93.3) 377 (90.2) 4 (4.0) 32 (15.2) 193 (100) 107 (74.8) 100 (100) 43 (58.9) 29 (59.2) 27 (100) NA 
SAMA, n (%) NA NA NA 175 (15.5) 38 (19.7) 25 (17.5) 0 (0) 28 (38.0) 1 (2.0) 8 (29.6) NA 
LABA, n (%) 436 (92.2) 457 (97.4) 219 (100)  206 (97.2) 155 (80.3) 135 (94.4) 100 (100) 72 (98.0) 43 (87.8) 27 (100) NA 
LAMA, n (%) 269 (56.8) 113 (24.1) 40 (40.4)  35 (28.9) 37 (19.2) 42 (29.4) 14 (14) 54 (73.9) 22 (44.9) 8 (30) NA 
ICS, n (%) 477 (100) 457 (97.4) 219 (100)  212 (100) 193 (100) 142 (99.3) 100 (100) 73 (100) 46 (93.9) 27 (100) NA 
ICS mean dose*, µg/day (SD) 973 (508) 986 (479) 570 (497) 1320 (465) 1220 (668) 1178 (797) 909 (386) 700.1 (207.4) 
1073 (372) 
1196 (641) NA 
LTRA, n (%) 188 (41.6) 251 (55.0) 37 (37.4)  123 (58.6) 128 (66.3) 29 (20.3) 45 (45.0) 30( 41.09) 28 (57.1) 21 (77.8) NA 
Theophylline, n (%) 120 (25.3) 65 (14.0) 7 (7.1)  22 (11.2) 52 (26.9) 6 (4.2) 35 (35.0) 1 (1.3) 5 (10.2) 2 (7.4) NA 
OCS  
maintenance 




























NSAIDS, n (%) NA 25 (5.0) NA NA 44 (22.8) 3 (2.2) 0 (0) NA NA 20 (74.1) NA 
Data are represented as mean with standard deviation (SD) unless otherwise specified. IQR: Interquartile range from quartile 1 – quartile 3, GINA: Global 
Initiative for asthma, SABA: short-acting beta agonist, LAMA: short-acting muscarinic antagonists, LABA: long-acting beta agonists, LAMA: long-acting 
muscarinic antagonists, ICS: inhalation corticosteroids, LTRA: leukotriene receptor antagonists, OCS: oral corticosteroids, NSAIDS: non-steroidal anti-
inflammatory drugs. *: dose expressed as fluticasone equivalents, †: dose expressed as prednisone equivalents. 
  
 
Table 4. Biomarker data from patients before starting with biological therapies (anti-IL5 and anti-IgE). 




Belgium Spain Poland 
The 
Netherlands 
Hungary Slovenia Denmark Sweden Germany 
Before starting anti-IL5           
Blood eosinophils  x10
9
 cells/L, 




















Serum total IgE IU/ml, median 
(IQR) 
129 (44-404) 270 (90-376) 








FeNO  ppb, median (IQR) 54 (31-81) 43 (32-48) 48 (40-70) 27 (20-47) 36 (24-60) 52 (34-135) 89.5 (55-101) 38 (30-56) 57 (29-80) NA 
Before starting anti-IgE           




























154 (74-388) NA 
172 (118-
233) 
118 (32-795) 148 (92-228) NA NA 




Figure 1. Participating countries in the SHARP Fast Mover Project (FMP). 
 
Figure 2. Inclusion criteria and criteria for preselection of patients in the different registries. 
 
Figure 3.  A. Overview of maintenance treatment of patients that start with anti-Il5 biologicals, ICS: 
Inhalation Corticosteroids, LABA: long-acting beta agonist, LAMA: long-acting muscarinic antagonist, 
OCS: oral corticosteroids. B. Mean ICS dose, as fluticasone equivalents, in patients that start with 
anti-IL5 biological therapies. C. Median maintenance OCS dose with interquartile range (Q1-Q3), in 
prednisone equivalents, in patients that start with anti-IL5 biological therapies. Median values in: 
UK=10, ES=12.5, NL=10, SL=10, PL=9, HU=10, SE=10, BE=2.5 mg/day. 
 
Figure 4.  A. Overview of maintenance treatment of patients that start with anti-IgE biologicals, ICS: 
Inhalation Corticosteroids, LABA: long-acting beta agonist, LAMA: long-acting muscarinic antagonist, 
OCS: oral corticosteroids. B. Mean ICS dose, as fluticasone equivalents, in patients that start with 
anti-IgE biological therapies. C. Median maintenance OCS dose with interquartile range (Q1-Q3), in 
prednisone equivalents, in patients that start with anti-IgE biological therapies. Median values in: 
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Supplementary table 1. Baseline characteristics of patients enrolled in the national SHARP registries involved in the fast mover project.  
Parameter   NL Belgium 
United 
Kingdom 
Spain Hungary Poland Sweden Germany Italy Slovenia Denmark 
Demographic                         
Age n 237 629 765 410 130 193 27 209 434 140 59 
years  52,8 56,9 47,6 56,4 58,3 48,4 50 44,4 54,1 53,5 51,9 
SD 14,2 14,7 14,5 14,8 12,9 14,6 8,6 20,4 13,7 12,8 16,1 
Male n  112 265 285 133 42 76 14 98 183 42 28 
% 47,3 42,1 37,3 32,4 32,3 39,4 51,9 46,9 41,9 30 47,5 
Smoking status available n 235 629 734 410 130 193 27 209 437 140 50 
Current smoker n  2 60 30 29 8 0 0 5 12 1 2 
% 0,9 9,5 4,1 7,1 6,2 0 0 2,4 2,7 0,7 4 
Never smoker n 136 368 526 281 108 171 16 125 352 92 24 
% 57,9 58,5 71,7 68,5 83,1 88,6 59,3 59,8 80,5 65,7 48 
Ex-smoker n 97 201 178 100 14 22 11 79 73 47 19 
% 41,3 32 24,3 24,4 10,8 11,4 40,7 37,9 16,7 33,5 38 
Pack-years n 94 194 179 25 22 22 11 85 85 48 16 
years, median 10 15 15 19 <5 PY  NA 5 8 9 10 8,5 
Q1 4 6 5 10 <5 PY  NA 4 2 4 3 2,2 
Q3 19 27 20 23 <5 PY  NA 9 15 15 20 15 
Clinical                         
BMI  n 236 629 740 410 130 193 27 207 295 138 58 
kg/m2  28,3 27,7 30,6 28,2 26,9 28,1 27,7 27,4 26,2 27,1 27,1 
SD 5,4 12,6 7,4 6 5,4 4,48 5,3 10,8 5 5,8 5,4 
Pre-BD FEV1 n 234 607 669 87 130 193 27 182 285 140 50 
%pred  76,9 67,9 67,8 68,1 56 63,2 66 70,3 71,4 69,6 72,0 
SD 22,2 21,6 22,8 36,1 16,8 23,5 19,9 23 20,2 19,8 19,4 
Pre-BD FVC  n 234 607 647 NA 130 NA 27 182 280 137 49 
%pred  98,3 88,2 85,3 NA 76,6 NA 86,8 84,9 88,2 95 78,2 
SD 20,5 20,2 19,8 NA 18,5 NA 19,6 19,7 21,1 15,6 18,3 
Post-BD FEV1  n 152 629 374 NA 130 NA 27 65 193 NA NA 
%pred  81 75 73,4 NA 63 NA 73,2 70,2 77,8 NA NA 
SD 22,3 57,1 22,5 NA 17,5 NA 19 33,2 28,4 NA NA 
Post-BD FVC  n 152 NA 359 NA 130 NA 27 NA NA NA NA 
%pred  102,4 NA 90,7 NA 82,9 NA 91,7 NA NA NA NA 
SD 18 NA 20,1 NA 19,2 NA 14,5 NA NA NA NA 
PC20  n NA 55 12 NA NA NA NA NA NA NA NA 
mg/ml, median NA 0,93 14,8 NA NA NA NA NA NA NA NA 
Q1 NA 0,26 4 NA NA NA NA NA NA NA NA 
Q3 NA 7,66 16 NA NA NA NA NA NA NA NA 
KCO n 97 482 491 NA 16 NA 27 76 NA 49 NA 
%pred (SD) 98,2 97,3 97,3 NA 85,8 NA 79,3 76,7 NA 83,4 NA 
 
SD 18,8 20,9 38,9 NA 4,1 NA 15,9 21 NA 20,5 NA 
Medical history available n 204 629 644 410 130 193 27 170 301 140 33 
Adult onset n  129 200 385 NA 89 68 24 61 105 110 26 
% 63,2 31,8 59,8 NA 68,5 35,2 88,9 39,4 24 78 76,0 
Asthma hospitalization during past 
12 months 
n NA 229 291 52 36 78 1 55 53 61 16 
% NA 36 39,5 12,7 28 40,5 3,7 32,4 17,6 47,2 40,0 
Ever near fatal exacerbations n 31 76 NA 0 11 52 2 16 10 21 0 
% 13,1 12 NA 0 8 27 7,4 9,4 3,3 16,1 0 
ACQ n 143 439 687 NA NA 193 17 190 192 NA 33 
mean score 2,1 2,5 3 NA NA 3,3 1,8 2,6 2,9 NA 2,4 
SD 1,2 1,3 1,3 NA NA 0,9 1 1,5 1,5 NA 1,4 
ACT n NA 455 NA 327 130 28 10 196 266 136 NA 
mean score NA 13,2 NA 15,9 16,6 12,3 12 15 17,2 16,7 NA 
SD NA 5,4 NA 5,8 1,2   3,8 6 5,4 5,5 NA 
Uncontrolled asthma (based on 
ACQ/ACT score) 
n 88 331 581 221 130 191 27 135 250 87 21 
% 61,5 76,1 84,6 68,8 100 99 100 71,1 54,6 64 70,0 
Lab                          
Leukocytes 
n 232 NA NA NA 125 193 27 114 184 135 NA 
x10
9
 cells/L (SD) 9,1 NA NA NA 9,1 8,4 8,2 8,5 8,5 8,8 NA 
SD 2,8 NA NA NA 2,8 2,7 2,9 2,8 4,6 3,3 NA 
Eosinophils absolute 
n 225 516 749 199 125 193 27 111 228 132 45 
x10
9
 cells/L (median) 0,290 0,280 0,300 0,310 0,345 0,410 0,800 0,230 0,540 0,260 0,250 
Q1 0,105 0,114 0,200 0,100 0,140 0,200 0,600 0,100 0,190 0,120 0,100 
Q3 0,570 0,539 0,600 0,530 0,578 0,740 1,000 0,580 0,645 0,440 0,600 
Eosinophils relative 
n 32 517 NA NA 125 193 27 NA 201 134 NA 
% (SD) 5,2 7,3 NA NA 4,6 4,7 11,2 NA 6,2 4,1 NA 
SD 9,1 55,9 NA NA 3,9 4,6 5,7 NA 5,6 3,5 NA 
Neutrophils absolute 
n 222 NA NA NA 125 NA 27 100 183 134 NA 
x10
9
 cells/L (median) 5,48 NA NA NA 5,26 NA 3,80 5,02 4,75 5,16 NA 
Q1 4,09 NA NA NA 3,98 NA 2,90 3,71 3,12 3,60 NA 
Q3 7,25 NA NA NA 7,37 NA 5,10 7,15 5,66 6,80 NA 
Neutrophils relative 
n 27 NA NA NA 125 NA 27 100 134 132 NA 
% (SD) 65,2 NA NA NA 65,2 NA 52,2 62,7 52,4 62,7 NA 
SD 12,7 NA NA NA 12,1 NA 8,8 14,5 16,9 1,6 NA 
Total IgE (serum) 
n 222 533 739 199 65 193 20 66 260 139 36 
IU/ml, median (IQR) 144 190 165 236 164 168 275 197 272 238 164 
Q1 49 68 55 102 54,7 78 115 78 122 115 74 
Q3 368 513 491 516 385 435 820 579 561 358 283 
Positive for Aspergillus 
n (%) 29 NA NA 2 0 0 1 28 (molds)  24 NA NA 
% 12,4 NA NA 0,5 0 0 3,7 13,9 5,5 NA NA 
Negative for Aspergillus 
n (%) 103 NA NA NA 40 10 26 28 NA NA NA 
% 44 NA NA NA 30,7 5,2 96,3 13,9 NA NA NA 
 
No Aspergillus result available  
n (%) 102 NA NA NA 90 183 0 174 NA NA NA 
% 43,6 NA NA NA 69,2 94,8 0 86,1 NA NA NA 
FeNO  
n 213 450 540 85 69 8 26 7 132 122 50 
ppm, median (IQR) 33 25 41 33 32 27 57 33 32 66 26 
Q1 20 14 23 19 18 20 29 19 17 27 13 
Q3 60 42 77 52 56 47 80 79 64 101 49 
Comorbidities                         
Comorbidity data available n 236 622 765 121 130 193 27 201 162-298 139 NA 
Aspirin intolerance 
n (%) 38 49 NA 72 52 44 7 43 57 33 NA 
% 16,1 8,2 NA 17,6 40 22,8 26,9 21,4 19,1 23,7 NA 
Churg-Strauβ syndrome (EGPA) n (%) 6 18 NA 3 9 2 0 3 NA 4 NA 
% 2,5 3,1 NA 2,5 6,9 1 0 1,5 NA 2,8 NA 
ABPA 
n (%) 3 24 NA 1 0 0 0 1 NA 3 NA 
% 1,3 3,9 NA 0,8 0 0 0 0,5 NA 2,1 NA 
Nasal Polyps 
n (%) 107 151 102 295 58 24 9 NA 69 9 NA 
% 45,3 24,3 13,3 72 44,6 12,4 33 NA 42,6 6,4 NA 
Bronchiectasis 
n (%) 36 104 35 10 2 4 0 10 44 8 NA 
% 15,3 16,7 4,6 2,4 1,5 2,1 0 5 16,5 5,7 NA 
Therapy                     SI   
Therapy data available n 237 629 765 379 130 193 27 202 437 139 NA 
Included in primary care center n 0 0 0 16 0 0 0 NA 0 0 NA 
% 0 0 0 3,9 0 0 0 NA 0 0 NA 
Included in secondary care center n  76 52 0 125 44 0 0 NA 0 0 NA 
% 32,1 8,3 0 30,5 33,8 0 0 NA 0 0 NA 
Included in tertiary care center n 161 577 765 269 86 193 27 NA 437 139 NA 
% 67,9 91,7 100 65,6 66,2 100 100 NA 100 100 NA 
Medication use data available n 237 629 743 379 130 193 27 209 315 139 NA 
GINA step 4 treatment n 113 308 162 197 93 53 15 130 18 87 NA 
% 47,7 49 21,2 48,1 71,5 27,5 55,6 62,2 5,7 62,6 NA 
GINA step 5 treatment n 118 261 569 210 37 140 12 79 297 52 NA 
% 49,8 41,5 74,4 51,2 28,5 72,5 44,4 37,8 94,3 37,4 NA 
Data on adherence is available n 6 629 603 394 14 193 27 NA NA NA NA 
Adherence to therapy is checked n 6 629 519 332 14 193 27 NA NA NA NA 
% 2,5 100 86,1 84,3 10,8 100 100 NA NA NA NA 
On biological treatment n 82 185 479 210 30 137 0 80 215 66 NA 
% 34,6 29,4 64,5 51,2 23,1 71 0 38,3 49,5 47,4 NA 
Anti-IgE n  29 157 115 197 16 129 0 41 180 59 NA 
% 12,2 25 25,4 48,1 12,3 66,8 0 19,6 41,2 42,4 NA 
Anti-IL5 n  53 28 337 13 14 8 0 39 35 7 NA 
% 22,4 4,5 74,4 3,2 10,8 4,1 0 18,7 8,1 5 NA 
Anti-IL4/IL13 n  0 0 1 0 0 0 0 NA NA 0 NA 
% 0 0 0,2 0 0 0 0 NA NA 0 NA 
 
Received thermoplasty n  3 9 0 0 0 0 0 NA NA 2 NA 
% 1,3 1,4 0 0 0 0 0 NA NA 1,4 NA 
Received high altitude treatment n  33 0 NA 0 0 0 0 NA NA 0 NA 
% 14 0 NA 0 0 0 0 NA NA 0 NA 
ICS mean fluticasone equivalent  n 234 627 654 251 130 193 27 198 299 138 NA 
µg/day (SD) 1027 954 934 1225 920 1220 1196 676 542 491 NA 
SD 737 501 449 445 370 668 641 398 489 163 NA 
OCS maintenance, mean  n 119 137 415 146 37 87 17 79 199 52 NA 
mg/day (median) 10,0 9,0 10,0 10,0 7,5 7,0 10,0 10,0 10,7 10,0 NA 
Q1 5,0 5,0 10,0 5,0 5,0 7,0 7,5 5,0 5,0 5,0 NA 
Q3 17,5 10,0 20,0 10,0 10,0 15,0 10,0 15,0 20,0 10,0 NA 
SD: standard deviation, IQR: Interquartile range from quartile 1 – quartile 3, BMI: body mass index, FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, BD: Broncho-
dilator, PC20: provocative concentration causing a 20% drop in FEV1, KCO: Carbon monoxide diffusion, FeNO: fraction of exhaled Nitric Oxide, ACQ: asthma control questionnaire, ACT: asthma 
control test, GINA: Global Initiative for asthma, ICS: inhalation corticosteroids, OCS: oral corticosteroids. *: dose expressed as fluticasone equivalents, 
†
: dose expressed as prednisone 
equivalents. 
Supplementary table 2. Baseline characteristics of patients enrolled in the national SHARP registries involved in the fast mover project.  
Parameter   NL Belgium 
United 
Kingdom 
Spain Hungary Poland Sweden Germany Italy Slovenia Denmark 
Demographic                         
Age n 143 471 479 212 100 193 27 NA 219 74 56 
years  55,5 57 48,6 57,9 61 48,4 50 NA 55,1 54,8 53,1 
SD 13,1 14 14,1 13,7 12,7 14,6 8,6 NA 13,8 12,2 15,6 
Male n  81 184 196 76 37 76 14 NA 95 19 26 
% 56,6 39,1 40,9 35,8 37 39,4 51,9 NA 42,8 25,6 46,4 
Smoking status available n 143 471 458 212 100 193 27 NA 219 74 47 
Current smoker n  0 49 6 8 7 0 0 NA 5 1 2 
% 0 10,4 1,3 3,8 7 0 0 NA 2,3 1,3 4,3 
Never smoker n 81 273 343 153 80 171 16 NA 186 47 22 
% 56,6 58 74,9 72,2 80 88,6 59,3 NA 84,9 63,5 46,8 
Ex-smoker n 62 149 109 50 13 22 11 NA 31 26 18 
% 43,4 31,6 23,8 23,6 13 11,4 40,7 NA 14,1 35,1 38,3 
Pack-years n 62 199 97 12 20 22 11 NA 36 27 15 
years, median 10 15 15 20 <5 NA 5 NA 8 10 10 
Q1 4 6 8 5 <5 NA 4 NA 7 2 4 
Q3 20 30 20 25 <5 NA 9 NA 15 22 15 
Clinical                         
BMI  n 143 471 466 212 100 193 27 NA 95 74 55 
kg/m2  28,3 27,8 30,6 27,8 27 28,2 27,7 NA 26,5 27,4 27,3 
SD 5,2 14,5 6,6 5,6 5,3 4,48 5,3 NA 5,3 6,3 5,4 
Pre-BD FEV1 n 142 456 421 26 100 193 27 NA 98 74 48 
 
%pred  75,7 67,8 65,2 63,9 56 63,2 66 NA 74,2 64,9 71,8 
SD 23,4 22,3 21,8 21,4 16,8 23,5 19,9 NA 20,6 18,9 19,3 
Pre-BD FVC  n 142 456 408 NA 100 NA 27 NA 96 71 47 
%pred  96,5 87,9 85,1 NA 76,2 NA 86,8 NA 90,6 93,2 78,1 
SD 21,2 20,8 19,7 NA 19 NA 19,6 NA 20,7 15,4 18,5 
Post-BD FEV1  n 107 471 221 NA 100 NA 27 NA 60 NA NA 
%pred  80,3 73,5 71,5 NA 61,5 NA 73,2 NA 73,4 NA NA 
SD 23,1 29,4 22,7 NA 17,5 NA 19 NA 24,8 NA NA 
Post-BD FVC  n 107 NA 209 NA 100 NA 27 NA NA NA NA 
%pred  101,8 NA 90,8 NA 81,3 NA 91,7 NA NA NA NA 
SD 17,4 NA 20,4 NA 19 NA 14,5 NA NA NA NA 
PC20  n NA 48 2 NA NA NA NA NA NA NA NA 
mg/ml, median NA 1,1 13,3 NA NA NA NA NA NA NA NA 
Q1 NA 0,3 3,6 NA NA NA NA NA NA NA NA 
Q3 NA 8 23 NA NA NA NA NA NA NA NA 
KCO n 74 374 312 NA 12 NA 27 NA NA 22 NA 
%pred (SD) 97,5 97,5 98,8 NA 86,3 NA 79,3 NA NA 84,4 NA 
SD 17,8 20,4 47,1 NA 4,6 NA 15,9 NA NA 14,8 NA 
Medical history available n 120-137 471 400 212 100 193 27 NA 97-158 74 32 
Adult onset n  85 155 246 NA 72 68 24 NA 49 60 26 
% 70,8 32,9 61,5 NA 72 35,2 88,9 NA 22,4 81,1 81,2 
Asthma hospitalization during past 
12 months 
n NA 170 180 193 27 78 1 NA 19 33 NA 
% NA 36,1 38,9 91 27 40,5 3,7 NA 19 47,8 NA 
Ever near fatal exacerbations n 21 50 NA 0 8 52 2 NA 3 13 0 
% 14,7 10,6 NA 0 8 26,9 7,4 NA 3 18,8 0 
ACQ n 90 330 436 NA NA 193 17 NA 74 NA 30 
mean score 2,3 2,6 2,9 NA NA 3,3 1,8 NA 2,6 NA 2,4 
SD 1,3 1,3 1,4 NA NA 0,9 1 NA 1,4 NA 1,4 
ACT n NA 345 NA 150 100 28 10 NA 84 70 NA 
mean score NA 12,6 NA 14,9 16,7 12,3 12 NA 16,4 15,8 NA 
SD NA 5,1 NA 5,4 1,2   3,8 NA 5,5 5,1 NA 
Uncontrolled asthma (based on 
ACQ/ACT score) 
n 88 261 363 114 100 191 27 NA 96 53 21 
% 96,7 79,1 83,3 76 100 99 100 NA 60,8 75,3 70,0 
Lab                          
Leukocytes n 142 NA NA NA 97 193 27 NA 67 72 NA 
x109 cells/L (SD) 9 NA NA NA 9,07 8,4 8,24 NA 8,46 9,2 NA 
SD 2,3 NA NA NA 2,77 2,7 2,9 NA 3,62 3,62 NA 
Eosinophils absolute n 141 388 474 125 97 193 27 NA 75 72 45 
x109 cells/L (median) 0,360 0,260 0,400 0,600 0,325 0,410 0,800 NA 0,660 0,280 0,250 
Q1 0,165 0,111 0,200 0,150 0,120 0,200 0,600 NA 0,200 0,140 0,100 
Q3 0,610 0,500 0,600 0,600 0,548 0,740 1,000 NA 0,750 0,460 0,600 
Eosinophils relative n 4 389 NA NA 97 193 27 NA 74 72 NA 
 
% (SD) 20,7 8,1 NA NA 4,2 4,7 11,2 NA 6,9 4,2 NA 
SD 18,1 65,6 NA NA 3,5 4,6 5,7 NA 5,9 3,3 NA 
Neutrophils absolute n 141 NA NA NA 97 NA 27 NA 41 72 NA 
x10
9
 cells/L (median) 5,46 NA NA NA 5,25 NA 3,80 NA 4,80 5,60 NA 
Q1 4,16 NA NA NA 3,90 NA 2,90 NA 3,44 3,70 NA 
Q3 7,23 NA NA NA 7,48 NA 5,10 NA 5,08 7,50 NA 
Neutrophils relative n NA NA NA NA 97 NA 27 NA 33 72 NA 
% (SD) NA NA NA NA 65,1 NA 52,2 NA 54,7 62,7 NA 
SD NA NA NA NA 12,3 NA 8,8 NA 15,6 12,1 NA 
Total IgE (serum) n 141 403 467 58 39 193 20 NA 71 52 36 
IU/ml, median (IQR) 144 147 172 250 181 168 275 NA 159 149 164 
Q1 49 51 58 117 41 78 115 NA 83 204 74 
Q3 379 453 467 520 445 435 820 NA 392 271 283 
Positive for Aspergillus n (%) 16 NA NA 0 0 0 1 NA 6 NA NA 
% 11,2 NA NA 0 0 0 3,7 NA 6 NA NA 
Negative for Aspergillus n (%) 64 NA NA 212 28 10 26 NA NA NA NA 
% 44,8 NA NA 100 28 5,2 96,3 NA NA NA NA 
No Aspergillus result available  n (%) 63 NA NA 0 72 183 0 NA NA NA NA 
% 44,1 NA NA 0 72 94,8 0 NA NA NA NA 
FeNO  n 125 365 293 58 60 8 26 NA 58 66 48 
ppm, median (IQR) 36 25 50 37 32 27 57 NA 34 63 27 
Q1 24 14 28 21 18 20 29 NA 21 31 14 
Q3 60 42 81 62 54 47 80 NA 67 101 52 
Comorbidities                         
Comorbidity data available n 143 445 479 43 100 193 27 NA 49-98 73 NA 
Aspirin intolerance n (%) 25 40 NA 49 40 44 7 NA 16 19 NA 
% 17,5 8,9 NA 23,1 40 22,8 25,9 NA 16,7 26 NA 
Churg-Strauβ syndrome (EGPA) n (%) 4 10 NA 3 6 2 0 NA NA 4 NA 
% 2,8 2,3 NA 1,4 6 1 0 NA NA 5,4 NA 
ABPA n (%) 1 18 NA 1 0 0 0 NA NA 2 NA 
% 0,7 4 NA 0,5 0 0 0 NA NA 2,7 NA 
Nasal Polyps n (%) 75 113 70 163 48 24 9 NA 26 4 NA 
% 52,4 25,4 14,6 76,9 48 12,4 33 NA 53,1 10,8 NA 
Bronchiectasis n (%) 21 83 27 10 2 4 0 NA 20 6 NA 
% 14,7 18,7 5,6 4,7 2 2,1 0 NA 20,4 8,2 NA 
SD: standard deviation, IQR: Interquartile range from quartile 1 – quartile 3, BMI: body mass index, FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity, BD: Broncho-
dilator, PC20: provocative concentration causing a 20% drop in FEV1, KCO: Carbon monoxide diffusion, FeNO: fraction of exhaled Nitric Oxide, ACQ: asthma control questionnaire, ACT: asthma 
control test, GINA: Global Initiative for asthma. 
 
 
Supplementary table 3. Medication use and biomarker data from patients that are starting with anti-IL5 therapy (mepolizumab, reslizumab, benralizumab). 
Medication use   NL Belgium 
United 
Kingdom 
Spain Hungary Poland Sweden Germany Italy Slovenia Denmark 
Medication data available n 142 12 337 13 14 8 27 NA NA 24 38 
Treatment according to GINA 
guidelines 
  
                    
  
GINA step 4 n 50 7 90 10 9 0 15 NA NA 7 NA 
% 36,5 58,3 26,8 76,9 64,3 0 55,6 NA NA 29,2 NA 
GINA step 5 n 85 3 246 3 5 4 12 NA NA 17 NA 
% 62 25 73,2 23,1 35,7 50 44,4 NA NA 70,8 NA 
Medication use                         
SABA n 107 10 315 6 14 8 27 NA NA 17 21 
% 74,8 83,3 94 46,2 100 100 100 NA NA 70,8 55,3 
SAMA n 25 NA NA 5 0 1 8 NA NA 5 4 
% 17,5 NA NA 38,5 0 12,5 29,6 NA NA 20,8 10,5 
LABA n 135 9 302 13 14 2 27 NA NA 24 33 
% 94,4 75 90,7 100 100 25 100 NA NA 100 86,8 
LAMA n 42 6 190 3 0 1 8 NA NA 19 17 
% 29,4 50 57,1 23,1 0 12,5 30 NA NA 79,1 44,7 
ICS n 142 12 337 13 14 8 27 NA NA 24 36 
% 100 100 100 100 100 100 100 NA NA 100 94,7 
Mean fluticasone equivalent  n 142 12 283 4 14 8 27 NA NA 24 33 
µg 1178 935 998 888 893 1335 1196 NA NA 700 1076 
SD 797 618 597 121 189 529 641 NA NA 118 345 
Leukotriene receptor antagonists n 29 8 135 10 10 5 21 NA NA 15 24 
% 20,4 66,7 41,5 76,9 71,4 62,5 77,8 NA NA 62,5 63,2 
Theophylline n 6 0 84 0 6 3 2 NA NA 0 5 
% 4,2 0 25,2 0 42,9 37,5 7,4 NA NA 0 13,2 
OCS n 87 2 246 3 5 4 17 NA NA 17 18 
% 61,3 16,7 73,2 23,1 35,7 50 63 NA NA 70,8 47,4 
Maintenance treatment, prednisone 
eq. Dose 
n 87 2 246 4 5 4 17 NA NA 17 NA 
DDD † 1,4 NA NA 1,54 0,95 NA 0,94 NA NA NA NA 
SD 1,1 NA NA 1,43 0,11 NA 0,29 NA NA NA NA 
Mg/day (median) 10,0 2,5 10,0 12,5 10,0 9,0 10,0 NA NA 10,0 NA 
Q1 7,5 1,9 10,0 9,3 8,1 5,5 7,5 NA NA 5,0 NA 
Q3 20,0 6,3 20,0 10,0 10,0 13,5 10,0 NA NA 12,5 NA 
NSAIDS n 3 1 NA NA 0 2 20 NA NA NA NA 
% 2,1 8,3 NA NA 0 25 74,1 NA NA NA NA 
Biomarkers                         
IgE n 140 6 331 10 10 8 20 NA NA 15 28 
Iu/ml, median (IQR) 140 165 129 431 56 405 275 NA NA 149 164 
Q1 48 154 44 168 29 360 115 NA NA 53 58 
 
Q3 366 217 404 594 200 791 820 NA NA 256 342 
Blood eosinophils, absolute n 141 9 336 12 14 8 27 NA NA 23 37 
x109 cells/l (median) 0,360 0,490 0,400 0,530 0,685 0,565 0,800 NA NA 0,440 0,270 
Q1 0,165 0,320 0,300 0,330 0,233 0,405 0,600 NA NA 0,280 0,100 
Q3 0,610 0,760 0,700 0,830 1,010 0,855 1,000 NA NA 0,670 0,600 
FeNO n 125 5 192 11 3 8 26 NA NA 24 38 
ppm, median (IQR) 36 27 54 48 52 27 57 NA NA 90 38 
Q1 24 26 31 40 34 20 29 NA NA 55 30 
Q3 60 62 81 70 135 47 80 NA NA 101 56 
SD: standard deviation, IQR: Interquartile range from quartile 1 – quartile 3, GINA: Global Initiative for asthma, SABA: short-acting beta agonist, LAMA: short-acting muscarinic antagonists, 
LABA: long-acting beta agonists, LAMA: long-acting muscarinic antagonists, ICS: inhalation corticosteroids, LTRA: leukotriene receptor antagonists, OCS: oral corticosteroids, NSAIDS: non-
steroidal anti-inflammatory drugs, FeNO: fraction of exhaled nitric oxide. *: dose expressed as fluticasone equivalents, 
†
: dose expressed as prednisone equivalents. 
 
 
Supplementary table 4. Medication use and biomarker data from patients that are starting with anti-IgE therapy (omalizumab). 
Medication use   NL Belgium UK Spain Hungary Poland Sweden Germany Italy Slovenia Denmark 
Medication data available n NA 87 115 197 16 129 NA NA NA 9 11 
Treatment according to GINA 
guidelines 
  
                    
  
GINA step 4 n NA 23 50 156 10 69 NA NA NA 8 NA 
% NA 26,4 43,9 79,2 62,5 53,5 NA NA NA 88,9 NA 
GINA step 5 n NA 56 64 41 6 60 NA NA NA 1 NA 
% NA 64,4 56,1 20,8 37,5 46,5 NA NA NA 11,1 NA 
Medication use                         
SABA n NA 75 107 16 16 129 NA NA NA 5 8 
% NA 86,2 93,9 8,1 100 100 NA NA NA 55,5 72,7 
SAMA n NA NA NA 169 0 26 NA NA NA 4 0 
% NA NA NA 85,8 0 20,2 NA NA NA 44,4 0 
LABA n NA 88 109 161 16 110 NA NA NA 9 10 
% NA 100 96,5 81,7 100 85,3 NA NA NA 100 90 
LAMA n NA 18 63 32 2 26 NA NA NA 9 5 
% NA 20,7 55,3 16,2 12,5 20,2 NA NA NA 100 45,5 
ICS n NA 84 115 197 16 129 NA NA NA 9 10 
% NA 96,6 100 100 100 100 NA NA NA 100 90,9 
Mean fluticasone equivalent  n NA 84 107 197 16 129 NA NA NA 9 8 
µg NA 881 923 1344 1016 1239 NA NA NA 772 1063 
SD NA 571 201 540 392 677 NA NA NA 191 496 
Leukotriene receptor antagonists n NA 54 46 113 12 86 NA NA NA 4 4 
% NA 62,1 43,8 57,4 75 66,7 NA NA NA 44 36,4 
Theophylline n NA 9 31 22 4 34 NA NA NA 0 0 
% NA 10,3 27,2 11,2 25 26,4 NA NA NA 0 0 
 
OCS n NA 10 64 41 6 60 NA NA NA 1 1 
% NA 11,5 56,1 20,8 37,5 46,5 NA NA NA 11,1 9,1 
Maintenance treatment, prednisone 
eq. Dose 
n NA 4 64 44 6 60 NA NA NA 1 NA 
DDD 
†
 NA NA NA 1,86 0,88 NA NA NA NA NA NA 
SD NA NA NA 0,81 0,7 NA NA NA NA NA NA 
Mg/day (median) NA 9,0 13,0 10,7 5,0 7,0 NA NA NA 7,5 NA 
Q1 NA 7,3 10,0 5,0 4,4 5,0 NA NA NA NA NA 
Q3 NA 10,0 20,0 15,0 16,3 15,0 NA NA NA NA NA 
NSAIDS n NA 5 NA NA 0 27 NA NA NA NA NA 
  % NA 5,7 NA NA 0 20,9 NA NA NA NA NA 
Biomarkers                         
IgE n NA 69 110 177 16 129 NA NA NA 5 8 
Iu/ml, median (IQR) NA 277 324 243 172 154 NA NA NA 118 148 
Q1 NA 132 139 114 118 74 NA NA NA 32 91,5 
Q3 NA 576 567 515 233 388 NA NA NA 795 228,3 
Blood eosinophils, absolute n NA 31 113 113 14 129 NA NA NA 8 8 
x10
9
 cells/l (median) NA 0,250 0,300 0,420 0,210 0,220 NA NA NA 0,235 0,13 
Q1 NA 0,166 0,100 0,200 0,150 0,100 NA NA NA 0,150 0,1 
Q3 NA 0,310 0,500 0,600 0,438 0,510 NA NA NA 0,370 0,3 
FeNO n NA 52 77 47 6 NA NA NA NA 6 10 
ppm, median (IQR) NA 31 39 36 34 NA NA NA NA 75 10 
Q1 NA 13 24 20 27 NA NA NA NA 40,5 11,8 
Q3 NA 49 82 57 80 NA NA NA NA 92,2 29,8 
SD: standard deviation, IQR: Interquartile range from quartile 1 – quartile 3, GINA: Global Initiative for asthma, SABA: short-acting beta agonist, LAMA: short-acting muscarinic antagonists, 
LABA: long-acting beta agonists, LAMA: long-acting muscarinic antagonists, ICS: inhalation corticosteroids, LTRA: leukotriene receptor antagonists, OCS: oral corticosteroids, NSAIDS: non-
steroidal anti-inflammatory drugs, FeNO: fraction of exhaled nitric oxide. *: dose expressed as fluticasone equivalents, 
†
: dose expressed as prednisone equivalents. 
 
 
 
 
